economictimes.indiatimes.com
Positiveeconomictimes.indiatimes.com ·
Zydus Lifesciences Shares Soar 7 to Fresh Record High After Q4 Results Should You Buy Sell or Hold
Currency Exchange RateDirectorsEcon PriceEconomy
Topic context
This topic has been covered 318020 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedZydus Lifesciences reported strong Q4 results with double-digit revenue and profit growth, leading to a 7% stock price surge. The company's improved margins and capital return (buyback, dividend) signal financial health. Sector: PHARMA_BIOTECH. Impact is company-specific; no broader sector or supply chain disruption identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Zydus Lifesciences Q4 FY26 net profit up 9% YoY to Rs 1,272.5 crore
- Revenue from operations grew >16% YoY to Rs 7,587 crore
- EBITDA margin improved to 33.7%
- Announced Rs 1,100 crore share buyback at Rs 1,150 per share
- Recommended final dividend of Re 1 per share
